Work

FC13 DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics

Year: 2010

Type: conference-abstract

Source: Melanoma Research

DOI: 10.1097/01.cmr.0000382815.90748.46

Authors: U. Trefzer, T. Jouary, C. Robert, M. Santinami, E. Levchenko, B. Smithers, A. Testori, O. Peeters, J. Kirkwood, B. Dréno

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1979569653

Cites:

Cited by: 5

Related to: 10